Patents by Inventor Allan Robins

Allan Robins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11905530
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: February 20, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz
  • Publication number: 20210102173
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 8, 2021
    Applicant: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz
  • Publication number: 20180320142
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Application
    Filed: April 30, 2018
    Publication date: November 8, 2018
    Applicant: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz
  • Patent number: 9988604
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: June 5, 2018
    Assignee: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz
  • Patent number: 9982235
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: May 29, 2018
    Assignee: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz
  • Publication number: 20160369239
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Application
    Filed: July 7, 2015
    Publication date: December 22, 2016
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz
  • Publication number: 20160281058
    Abstract: The present invention relates to compositions and methods for inhibiting or suppressing undifferentiated or pluripotent stem cell growth and proliferation in a differentiated or differentiating cell population or culture.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Inventors: Thomas Schulz, Allan Robins
  • Publication number: 20160194372
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Application
    Filed: July 23, 2015
    Publication date: July 7, 2016
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz
  • Patent number: 9365830
    Abstract: The present invention relates to compositions and methods for inhibiting or suppressing undifferentiated or pluripotent stem cell growth and proliferation in a differentiated or differentiating cell population or culture.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: June 14, 2016
    Assignee: VIACYTE, INC.
    Inventors: Thomas Schulz, Allan Robins
  • Patent number: 9109245
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: August 18, 2015
    Assignee: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schultz
  • Publication number: 20130280802
    Abstract: The present invention relates to compositions and methods for inhibiting or suppressing undifferentiated or pluripotent stem cell growth and proliferation in a differentiated or differentiating cell population or culture.
    Type: Application
    Filed: December 8, 2010
    Publication date: October 24, 2013
    Applicant: ViaCyte, Inc
    Inventors: Thomas Schulz, Allan Robins
  • Publication number: 20080085557
    Abstract: The present invention provides compositions and methods for the culture and maintenance of cancer stem cells. More particularly, the present invention provides the identification of cancer stem cell specific markers and methods of recognizing the same for the detection of tumors, for facilitating the prognosis of a patient with a tumor, and for the treatment of various cancers. The invention also provides antibodies that specifically recognize the disulfide linked Erbb2?16 homodimer, an Erbb2?16/Erbb3 heterodimer, or post-translational modifications of Erbb2 that are specific to Erbb2 of variant hESCs. In addition, the invention provides a modified defined media useful in the absence of a feeder layer and in the absence of serum or serum replacement, that comprises a basal salt nutrient solution, bFGF, IGF-I, and Activin A, and wherein the composition does not comprise heregulin.
    Type: Application
    Filed: June 18, 2007
    Publication date: April 10, 2008
    Inventors: Allan Robins, Thomas Schulz
  • Publication number: 20060211111
    Abstract: The present invention provides compositions and methods for mammalian neural cell production, their stabilization and their proliferation. More particularly, the present invention provides cellular differentiation methods employing culturing the cells on a cell line or in cell culture and further contacting the cells with MEDII conditioned medium for the generation of stable mammalian neural cells from pluripotent mammalian stem cells. The invention further provides methods for the stabilization of a neural cell in culture comprising contacting the neural cell with MEDII conditioned medium. Preferably, the stabilized neural cell is a neural progenitor cell.
    Type: Application
    Filed: December 18, 2003
    Publication date: September 21, 2006
    Inventors: Maisam Mitalipova, Ian Lyons, Brian Condie, Allan Robins, Scott Noggle
  • Publication number: 20060194315
    Abstract: The current invention relates to the control and/or manipulation of the gamma-secretase signaling pathway in pluripotent cells to stabilize the cells in a pluripotent state and/or to control the differentiation of the pluripotent cells towards a differentiated state. The invention further includes feeder layers that contain or express ligands or other compounds that inhibit gamma-secretase or Notch signaling to enhance the maintenance of pluripotent cells in a pluripotent state. The invention also includes cell culture compositions that comprise pluripotent cells and inhibitors of gamma-secretase, or activators or inhibitors of Notch signaling.
    Type: Application
    Filed: March 31, 2004
    Publication date: August 31, 2006
    Inventors: Brian Condie, Allan Robins, Scott Noggle
  • Publication number: 20060183221
    Abstract: The present invention provides methods for human pluripotent cell culturing and for neural cell production. More particularly, the present invention provides culturing methods employing dissociating cell cultures to an essentially single cell culture, such as by employing antibody selection and bulk passaging treatments utilizing the subsequent application of Collagenase and trypsin. In certain embodiments, the cells are further treated with essentially serum free MEDII conditioned medium, proline, or minimal medium, and are optionally treated with amphiphilic lipid compounds for the generation of human neural cells from pluripotent human cells. In certain embodiments, the cells cultured using these methods have an abnormal karyotype.
    Type: Application
    Filed: March 31, 2004
    Publication date: August 17, 2006
    Inventors: Thomas Schulz, Brian Condle, Allan Robins
  • Patent number: 6322791
    Abstract: The present invention relates generally to variant recombinant forms of haemopoietic growth factors useful as antagonists to the corresponding native haemopoietic growth factor and their use in ameliorating aberrant effects caused by the native molecules and in the treatment of tumours and cancers and inflammation.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: November 27, 2001
    Assignee: BreasaGen Limited
    Inventors: Mathew Alexander Vadas, Angel Francisco Lopez, Mary Francis Shannon, Keat-Chye Cheah, Carol Ruth Senn, Stan Bastiras, Allan Robins